A5073836342- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Advanced Radiotherapy Techniques
- Chronic Lymphocytic Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Head and Neck Cancer Studies
- Advances in Oncology and Radiotherapy
- Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Radiation Dose and Imaging
- Radiation Therapy and Dosimetry
- Genetic factors in colorectal cancer
- Brain Metastases and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Inflammatory Biomarkers in Disease Prognosis
- Vibrio bacteria research studies
Ottawa Hospital
2015-2025
University of Ottawa
2015-2024
Princess Margaret Cancer Centre
2024
University Health Network
2024
London School of Hygiene & Tropical Medicine
2024
Barts Health NHS Trust
2024
Ottawa Hospital Research Institute
2014-2024
Ottawa Public Health
2022
NRG Oncology
2016
The University of Texas Southwestern Medical Center
2016
Purpose Although intensity-modulated radiation therapy (IMRT) is increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimensional conformal external beam (3D-CRT) have not been compared prospectively. This study compares 3D-CRT outcomes for NSCLC in a large prospective clinical trial. Patients Methods A secondary analysis was performed compare with NRG Oncology trial RTOG 0617, which patients received concurrent chemotherapy of carboplatin paclitaxel...
A recent randomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a lower survival rate the high-dose therapy (RT) arm (74 Gy) than low-dose (60 with concurrent chemotherapy.The primary QOL hypothesis predicted clinically meaningful decline quality of life (QOL) via Functional Assessment Cancer (FACT)-Lung Subscale (LCS) RT at 3 months.The RTOG 0617 was phase study (conducted from November...
7501 Background: The first objective of RTOG 0617 was to compare the overall survival(OS) patients(pts) treated with standard-dose(SD)(60Gy) versus high-dose(HD)(74Gy) radiotherapy concurrent chemotherapy(CT). Methods: This Phase III Intergroup trial randomized 464 pts Stage NSCLC SD(60Gy) vs. HD(74Gy) arms prior closure HD arm. Concurrent CT included weekly paclitaxel(45 mg/m2) and carboplatin(AUC=2). Pts cetuximab received a 400 mg/m2 loading dose on Day 1 followed by doses 250 mg/m2. All...
Purpose: To retrospectively compare the sensitivity of image-guided core-needle biopsy, thoracoscopy, and thoracotomy in diagnosis malignant pleural mesothelioma to determine incidence needle track seeding after these procedures. Materials Methods: Institutional review board approval was obtained, informed consent not required. The study included 100 consecutive patients (81 men, 19 women; average age, 65.8 years) with pathologically proved who were treated between 1994 2002. A total 23...
Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing these therapies unclear. Our phase III trial compared neoadjuvant versus concurrent initiation ADT in combination dose-escalated RT (PRT).Patients newly diagnosed LPCa Gleason score ≤ 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly allocated for 6 months starting 4 before (neoadjuvant...
The optimal radiotherapy technique for unresectable locally advanced non-small cell lung cancer (NSCLC) is controversial, so evaluating long-term prospective outcomes of intensity-modulated (IMRT) important.
Background: Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (NSCLS) presenting rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those oncologists have consider balance efficacy quality life, while maximizing the duration line therapy ensuring that are still eligible later options, trial enrolment. Methods: An expert panel was convened define questions. Using case-based presentations,...
To what extent steroid hormones contribute to lung cancer in male and female never smokers is unclear. We examined expression of hormone receptors tumors by sex smoking. Patients with primary non–small cell were recruited into an Intergroup study the United States Canada, led SWOG (S0424). Tumors from 813 cases (450 women 363 men) assayed using immunohistochemistry for estrogen receptor (ER)–α, ER-β, progesterone (PR), human epidermal growth factor 2 (HER2). Linear regression was used...
Abstract Introduction Anti-osteoclast treatment with denosumab or zoledronate is known to effectively reduce the need for radiotherapy bone and other skeletal-related events (SREs) in patients metastatic castration-resistant prostate cancer (mCRPC). In this study, we analyze primary versus secondary initiation of bone-targeting agents (BTAs) relative first palliative dying mCRPC. Methods Provincial administrative databases from Ontario, Canada identified (2007-2018, n = 98 646) who received...
7087 Background: Concurrent chemoRT is standard of care for most patients with unresectable stage III A/B NSCLC but no chemotherapy regimen/schedule has been established. In a previous phase I study (Brade et. al, ASCO 2008), we reported that pemetrexed was the first 3rd generation deliverable at full dose concurrently RT and cisplatin. This combination further in this study. Methods: Starting April/07 to Aug/09, IIIA/B were entered on single arm II trial 5 Canadian centers. Eligibility: <...
7018 Background: Patients with stage 3 NSCLC are potentially curable using combined modality therapy (CMT) chemotherapy and radical radiation (RT). PET/CT imaging is commonly used to patients NSCLC. In addition, for planning of RT may improve the definition treatment volumes compared conventional CT thus outcomes. Methods: NSCLC, who were considered candidates CMT, randomized either or alone planning. The proportion did not receive CMT because their tumor was upstaged 4 intra-thoracic too...
The prediction of local recurrence (LR) stage I non-small cell lung cancer (NSCLC) after definitive stereotactic body radiotherapy (SBRT) remains elusive. purpose this study was to assess whether quantitative imaging features on pre-treatment computed tomography (CT) can predict LR beyond 18 (18F) fluorodeoxyglucose (18F-FDG) positron emission (PET)/CT maximum standard uptake value (SUVmax).This retrospective evaluated 36 patients with 37 NSCLC who had tumor control (LC; n=19) and (LR;...